- AdventHealth Research Institute
“We've known that Alzheimer's disease is a neurodegenerative disorder where there is a build-up of amyloid plaques and Tau neurofibrillary tangles in the brain, but we’ve been learning more in recent years. We now know there is also inflammation happening in the brain of patients with Alzheimer’s and that there is a potential immune response in the brain that is causing that inflammation and contributing to the brain’s degeneration and atrophy. Through the Exablate BBBD study, we’re exploring whether allowing the blood-brain barrier to be open for 24 to 48 hours could safely enable the patient’s innate immune system to better recognize and attack the plaques, tangles and inflammation.” – Valeria Baldivieso, MD, Medical Director of Memory Care, AdventHealth Central Florida
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer’s Disease clinical trial (NCT03671889). Exablate uses magnetic resonance-guided focused ultrasound (MRgFUS), a minimally invasive treatment where ultrasound waves pass through the skull and brain tissues to precisely heat and ablate a deep brain target while magnetic resonance (MR) imaging allows for treatment monitoring.
Click below to read more.
Recent News
The adventHealth is excited to announce the launch of the SOMMA study. This study aims to better understand how our muscles and mobility function change as we age.
We are proud to announce the launch of the new RISE study.
Dr. Iswanto Sucandy was recently featured on AdventHealth West Florida Division’s “Team Talk” to discuss his groundbreaking textbook.
AdventHealth Research Institute’s new review, authored by Drs. Katie Whytock and Bret Goodpaster and published in Circulation Research, highlights how skeletal muscle regulates insulin and glucose...
On July 10, 2025, AdventHealth Director of Neuroscience Clinical Research Anita Fletcher, MD, worked with NKGen Biotech to administer the first dose of troculeucel (SNK01), an investigative natural...
In our latest Clinician’s View, Dr. Seminerio shares her personal passion for improving care for patients with inflammatory bowel disease (IBD) and talks about how AdventHealth’s recently established...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative...
For people with Type 1 diabetes (T1D), low blood sugar episodes—also known as hypoglycemia—can strike fast and hard. The body’s natural defense is to release hormones like glucagon to raise blood...
A new study reveals that people newly diagnosed with Type 2 diabetes face a significantly higher risk of developing aggressive cancers—including those of the liver, pancreas, and colon.
Dr. Richard Pratley, Samuel E. Crockett Chair in Diabetes Research and Medical Director of AdventHealth Diabetes Institute, recently shared insights with Healio Endocrinology about the importance of...
Under the leadership of principal investigator Michael Seidman, MD, AdventHealth Research Institute is participating in the multi-site Clinical Trial of Etanercept (TNF-alpha Blocker) for Treatment of...
Metabolic dysfunction associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), affects about 70% of people with type 2 diabetes, placing them at...